Physician profile
Steven E Ross
NPI 1043409451
$2,808.22
in general payments reported to CMS, 2019-2025
25 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $53.28 · 2021: $12.69 · 2022: $23.64 · 2024: $325 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.28 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $305.41 | 2019-2025 | Otezla, Evenity, Krystexxa |
| Abbvie INC. | $274.50 | 2024-2025 | |
| Glaxosmithkline, LLC. | $264.03 | 2024-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $255.99 | 2024-2025 | Airsupra, Saphnelo, Breztri |
| Ucb, INC. | $246.16 | 2024-2025 | Bimzelx, Cimzia |
| Novo Nordisk INC | $237.77 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Biotech, INC. | $183.90 | 2025 | Tremfya |
| Abbott Laboratories | $150.37 | 2025 | Freestyle Libre 3 |
| Allergan, INC. | $147.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $140.33 | 2019-2025 | Orencia |
| Lilly USA, LLC | $122.32 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $106.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $90.03 | 2019-2025 | |
| Scpharmaceuticals INC. | $39.80 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $36.88 | 2025 | Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $28.67 | 2025 | Durolane |
| Sobi, INC | $28.02 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.67 | 2025 | Jascayd |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.64 | 2022 | |
| Coopersurgical, INC. | $20.02 | 2025 | Paragard T 380a |
| Medtronic, INC. | $19.43 | 2025 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $18.38 | 2024 | |
| Mallinckrodt Hospital Products INC. | $16.96 | 2025 | Acthar |
| Exact Sciences Corporation | $15.20 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.